Eli Lilly Receives FDA Approval for Omvoh in Ulcerative Colitis

Eli Lilly and Company today announced that the FDA has approved Omvoh (mirikizumab-mrkz) for the treatment of adults with moderately to severely active ulcerative colitis (UC). Omvoh is an IL-23 inhibitor that selectively targets the p19 subunit of IL-23. In the Phase 3 LUCENT-1 induction and LUCENT-2 maintenance trials, Omvoh demonstrated statistically significant improvements in clinical remission, endoscopic improvement, and bowel urgency compared to placebo. The approval of Omvoh provides patients with UC a new biologic treatment option. Lilly continues to study mirikizumab in Crohn's disease.